NFKB1 and colitis: In addition, studies have shown that Limosilactobacillus has antibacterial and immunological as well as intestinal barrier-enhancing properties, and also inhibits inflammation (Liu B. et al., 2022; Yakabe et al., 2022) and prevents the occurrence and progression of colitis by modulating the NF-κB signaling pathway (Liu B. et al., 2022).